Skip to main content
Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd. — Investor Relations & Filings

Ticker · 300759 ISIN · CNE100003JW4 LEI · 300300JYXHGVS5SNGG54 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2025-03-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300759

About Pharmaron Beijing Co., Ltd.

https://www.pharmaron.cn

Pharmaron Beijing Co., Ltd. is a premier R&D service provider for the life sciences industry, offering a comprehensive, fully integrated platform for drug discovery, development, and manufacturing. The company supports global pharmaceutical and biotechnology partners through a wide range of services, including laboratory chemistry, biology, DMPK, pharmacology, and safety assessment. Its capabilities extend to clinical development services and commercial-scale manufacturing for small molecules, biologics, and cell and gene therapies. By leveraging advanced technology and a global network of facilities, the company facilitates the transition of drug candidates from initial concept to market approval, optimizing the efficiency and success of the drug development lifecycle.

Recent filings

Filing Released Lang Actions
2024年度独立非执行董事述职报告（曾坤鸿）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立非执行董事述职报告" which translates to "2024 Annual Report of Independent Non-Executive Director's Work." It is a detailed report by an independent non-executive director about his duties, attendance, and activities during the year 2024. The content includes descriptions of board meetings, committee meetings, attendance records, independence confirmation, and oversight activities related to governance and compliance. It does not contain financial statements or audit results but focuses on the director's management and governance role. This aligns with the category of Board/Management Information (MANG), which covers announcements or reports about changes or activities of the company's board or senior management. The document is not an annual report (10-K), audit report (AR), or remuneration report (DEF 14A), nor is it a proxy or voting announcement. Therefore, the best fit is MANG with high confidence.
2025-03-26 Chinese
《股东大会议事规则》（2025年3月）
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting". It contains detailed procedural rules for convening, conducting, and voting in shareholders' meetings, including rights and obligations of shareholders, meeting notices, proposal submissions, voting procedures, and execution of resolutions. There is no financial data, earnings information, or report content. It is a governance document outlining internal rules and procedures related to shareholder meetings. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, supporting a high confidence classification.
2025-03-26 Chinese
2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including revenue, net profit, cash flow, shareholder information, business overview, and industry outlook. It also includes auditor's opinion (standard unqualified opinion) and detailed business descriptions. The length of the document is over 12,000 characters, indicating it is a substantive report rather than a brief announcement. The content matches the characteristics of an official yearly report covering company activity and full financial performance. Therefore, this document is classified as an Annual Report (10-K). FY 2024
2025-03-26 Chinese
2024年环境、社会及管治报告
Environmental & Social Information Classification · 100% confidence The document is titled as the "2024 Environment, Social and Governance Report" (环境、社会及管治报告) of 康龙化成（北京）新药技术股份有限公司. It contains detailed sections on ESG governance, sustainability initiatives, social responsibility, environmental protection, corporate governance structure, and performance highlights related to ESG factors. The report references compliance with ESG reporting standards such as those from the Hong Kong Stock Exchange, Shenzhen Stock Exchange, GRI standards, and MSCI ESG ratings. It includes quantitative performance data, governance statements, and detailed disclosures on environmental and social topics. There is no indication that this is an annual financial report, earnings release, or any other financial filing. Instead, it is a comprehensive ESG report focusing on environmental, social, and governance factors. Therefore, the appropriate classification is Environmental & Social Information (Code: SR). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or summary.
2025-03-26 Chinese
2024年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度董事会工作报告" (2024 Annual Board Work Report) of 康龙化成（北京）新药技术股份有限公司. It contains detailed information about the company's business operations, board composition changes, board meeting activities, committee reports, governance reviews, ESG progress, and outlook for 2025. The content is comprehensive and focuses on the board's activities, governance, and management oversight rather than just financial results or audit opinions. It includes detailed descriptions of board meetings, committee functions, governance policies, and strategic plans. This aligns with the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and detailed board activities. The document is not a full annual report (10-K), audit report (AR), or earnings release (ER), nor is it a proxy statement or voting results announcement. Therefore, the most appropriate classification is MANG with high confidence.
2025-03-26 Chinese
《董事、监事、高级管理人员持有和买卖本公司股票管理制度》（2025年3月）
Governance Information Classification · 95% confidence The document is a detailed management system outlining the rules and regulations for directors, supervisors, and senior management personnel regarding their holding and trading of the company's shares. It references relevant laws and regulatory frameworks such as the Company Law, Securities Law, Shenzhen Stock Exchange rules, Hong Kong Securities and Futures Ordinance, and the Listing Rules. The content focuses on internal governance policies related to insider trading, disclosure obligations, trading restrictions, and penalties for violations. There is no financial data, earnings information, or report publication announcement. The document is a governance-related policy document concerning internal rules and compliance practices for management share dealings. Therefore, it fits best under Governance Information (CGR).
2025-03-26 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.